Kamakshi Sishtla

Ms. Kamakshi Sishtla

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2018 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
SPSheik Pran Babu Sardar Pasha
Sheik Pran Babu Sardar Pasha
KSKamakshi Sishtla
Kamakshi Sishtla
RSRania S. Sulaiman
Rania S. Sulaiman
BPBomina Park
Bomina Park
TSTrupti Shetty
Trupti Shetty
Timothy CorsonTimothy Corson
Timothy Corson
Ocular neovascular diseases like wet age-related macular degeneration are a major cause of blindness. Novel therapies are greatly needed for these diseases. One appealing antiangiogenic target is reduction-oxidation factor 1–apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1). This protein can act as a redox-sensitive transcriptional activator for nuclear factor (NF)-κB and other proangiogenic transcription factors. An existing inhibitor of Ref-1’s function, APX3330, previously showed antiangiogenic effects. Here, we developed improved APX3330 derivatives and assessed their antiangiogenic activity. We synthesized APX2009 and APX2014 and demonstrated enhanced inhibition of Ref-1 function in a DNA-binding assay compared with APX3330. Both compounds were antiproliferative against human retinal microvascular endothelial cells (HRECs; GI50 APX2009: 1.1 μM, APX2014: 110 nM) and macaque choroidal endothelial cells (Rf/6a; GI50 APX2009: 26 μM, APX2014: 5.0 μM). Both compounds significantly reduced the ability of HRECs and Rf/6a cells to form tubes at mid-nanomolar concentrations compared with control, and both significantly inhibited HREC and Rf/6a cell migration in a scratch wound assay, reducing NF-κB activation and downstream targets. Ex vivo, APX2009 and APX2014 inhibited choroidal sprouting at low micromolar and high nanomolar concentrations, respectively. In the laser-induced choroidal neovascularization mouse model, intraperitoneal APX2009 treatment significantly decreased lesion volume by 4-fold compared with vehicle (P < 0.0001, ANOVA with Dunnett’s post-hoc tests), without obvious intraocular or systemic toxicity. Thus, Ref-1 inhibition with APX2009 and APX2014 blocks ocular angiogenesis in vitro and ex vivo, and APX2009 is an effective systemic therapy for choroidal neovascularization in vivo, establishing Ref-1 inhibition as a promising therapeutic approach for ocular neovascularization.

4 February 2025 in The FASEB Journal
Verified
Journal Article
Open access
GHGabriella Hartman
Gabriella Hartman
AMAnbukkarasi Muniyandi
Anbukkarasi Muniyandi
KSKamakshi Sishtla
Kamakshi Sishtla
EKEyram K. Kpenu
Eyram K. Kpenu
WMWILLIAM PHILLIP MILLER
WILLIAM PHILLIP MILLER
Timothy CorsonTimothy Corson
Timothy Corson
Retinal neovascularization impairs visual function and is a hallmark of several neovascular eye diseases, including retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR). Current treatments include intravitreal injections of anti‐vascular endothelial growth factor (VEGF) biologics, but these therapeutics are often accompanied by high treatment burden and resistance to therapy. Prior studies indicate that APE1/Ref‐1, a multifunctional protein with both endonuclease (APE1) and redox‐mediated transcriptional regulatory activity (Ref‐1), activates multiple pro‐angiogenic and pro‐inflammatory signaling pathways by chemically reducing key cysteine residues in transcription factors, thereby activating them. Here, we investigated the previously unexplored role of Ref‐1 in retinal neovascularization. We demonstrate that Ref‐1 is highly expressed in endothelial cells in human PDR and in the oxygen‐induced retinopathy (OIR) mouse model of retinal neovascularization. Ref‐1 is also highly expressed in microglia and astrocytes in OIR. A small molecule Ref‐1 redox inhibitor, APX2009, decreased retinal neovascularization in OIR after systemic delivery. In vitro, hypoxic endothelial cells did not exhibit upregulation of Ref‐1 but rather increased Ref‐1 nuclear localization. APX2009 decreased hypoxic endothelial cell proliferation and HIF‐1α transcriptional activation. Thus, Ref‐1 redox activity may be a novel therapeutic target for the treatment of retinal neovascularization, making APX2009 a promising systemic therapeutic approach for the treatment of vascular retinopathies such as ROP and PDR.

Verified
Journal Article
Open access
PDF file
MMMahmut Mijit
Mahmut Mijit
SLSheng Liu
Sheng Liu
KSKamakshi Sishtla
Kamakshi Sishtla
GHGabriella Hartman
Gabriella Hartman
Jun WanJun Wan
Jun Wan
MKMark Kelley
Mark Kelley
APE1/Ref-1 (apurinic/apyrimidinic endonuclease 1, APE1 or APEX1; redox factor-1, Ref-1) is a dual-functional enzyme with crucial roles in DNA repair, reduction/oxidation (redox) signaling, and RNA processing and metabolism. The redox function of Ref-1 regulates several transcription factors, such as NF-κB, STAT3, HIF-1α, and others, which have been implicated in multiple human diseases, including ocular angiogenesis, inflammation, and multiple cancers. To better understand how APE1 influences these disease processes, we investigated the effects of APEX1 knockdown (KD) on gene expression in human retinal endothelial cells. This abolishes both DNA repair and redox signaling functions, as well as RNA interactions. Using RNA-seq analysis, we identified the crucial signaling pathways affected following APEX1 KD, with subsequent validation by qRT-PCR. Gene expression data revealed that multiple genes involved in DNA base excision repair, other DNA repair pathways, purine or pyrimidine metabolism signaling, and histidine/one carbon metabolism pathways were downregulated by APEX1 KD. This is in contrast with the alteration of pathways by APEX1 KD in human cancer lines, such as pancreatic ductal adenocarcinoma, lung, HeLa, and malignant peripheral nerve sheath tumors. These results highlight the unique role of APE1/Ref-1 and the clinical therapeutic potential of targeting APE1 and pathways regulated by APE1 in the eye. These findings provide novel avenues for ocular neovascularization treatment.

8 November 2023 in Small
Verified
Journal Article
Open access
DCDhawal Chobisa
Dhawal Chobisa
AMAnbukkarasi Muniyandi
Anbukkarasi Muniyandi
KSKamakshi Sishtla
Kamakshi Sishtla
Timothy CorsonTimothy Corson
Timothy Corson
YYYoon Yeo
Yoon Yeo
Neovascular age‐related macular degeneration (nAMD) is a leading cause of vision loss in older adults. nAMD is treated with biologics targeting vascular endothelial growth factor; however, many patients do not respond to the current therapy. Here, a small molecule drug, griseofulvin (GRF), is used due to its inhibitory effect on ferrochelatase, an enzyme important for choroidal neovascularization (CNV). For local and sustained delivery to the eyes, GRF is encapsulated in microparticles based on poly(lactide‐co‐glycolide) (PLGA), a biodegradable polymer with a track record in long‐acting formulations. The GRF‐loaded PLGA microparticles (GRF MPs) are designed for intravitreal application, considering constraints in size, drug loading content, and drug release kinetics. Magnesium hydroxide is co‐encapsulated to enable sustained GRF release over >30 days in phosphate‐buffered saline with Tween 80. Incubated in cell culture medium over 30 days, the GRF MPs and the released drug show antiangiogenic effects in retinal endothelial cells. A single intravitreal injection of MPs containing 0.18 µg GRF releases the drug over 6 weeks in vivo to inhibit the progression of laser‐induced CNV in mice with no abnormality in the fundus and retina. Intravitreally administered GRF MPs prove effective in preventing CNV, providing proof‐of‐concept toward a novel, cost‐effective nAMD therapy.

Verified
Journal Article
Open access
PDF file
BPBomina Park
Bomina Park
SPSHEIK PRAN BABU SARDAR PASHA
SHEIK PRAN BABU SARDAR PASHA
KSKamakshi Sishtla
Kamakshi Sishtla
GHGabriella Hartman
Gabriella Hartman
XQXiaoping Qi
Xiaoping Qi
Timothy CorsonTimothy Corson
Timothy Corson
Neovascular or “wet” age-related macular degeneration (nAMD) is a leading cause of blindness among older adults. Choroidal neovascularization (CNV) is a major pathological feature of nAMD, in which abnormal new blood vessel growth from the choroid leads to irreversible vision loss. There is a critical need to develop novel therapeutic strategies to address limitations of the current anti-vascular endothelial growth factor biologics. Previously, we identified soluble epoxide hydrolase (sEH) as a possible therapeutic target for CNV through a forward chemical genetic approach. The purpose of this study was to validate sEH as a target by examining retinal expression of sEH protein and mRNA by immunohistochemistry and RNAscope in situ hybridization, respectively, and to assess the efficacy of an adeno-associated virus (AAV) vector designed to knock down the sEH gene, Ephx2, in the murine laser-induced (L-) CNV model. nAMD patient postmortem eye tissue and murine L-CNV showed overexpression of sEH in photoreceptors and retinal pigment epithelial cells. Ephx2 knockdown significantly reduced CNV and normalized mRNA expression levels of CNV-related inflammatory markers. Thus, this study further establishes sEH as a promising therapeutic target against CNV associated with nAMD.

9 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
TSTrupti Shetty
Trupti Shetty
KSKamakshi Sishtla
Kamakshi Sishtla
BPBomina Park
Bomina Park
MRMatthew J. Repass
Matthew J. Repass
Timothy CorsonTimothy Corson
Timothy Corson
The relationship between heme metabolism and angiogenesis is poorly understood. The final synthesis of heme occurs in mitochondria, where ferrochelatase (FECH) inserts Fe 2+ into protoporphyrin IX to produce proto-heme IX. We previously showed that FECH inhibition is antiangiogenic in human retinal microvascular endothelial cells (HRECs) and in animal models of ocular neovascularization. In the present study, we sought to understand the mechanism of how FECH and thus heme is involved in endothelial cell function. Mitochondria in endothelial cells had several defects in function after heme inhibition. FECH loss changed the shape and mass of mitochondria and led to significant oxidative stress. Oxidative phosphorylation and mitochondrial Complex IV were decreased in HRECs and in murine retina ex vivo after heme depletion. Supplementation with heme partially rescued phenotypes of FECH blockade. These findings provide an unexpected link between mitochondrial heme metabolism and angiogenesis. Abstract Figure: Highlights: Heme synthesis inhibition changes mitochondrial morphology in endothelial cells Loss of heme causes a buildup of mitochondrial ROS and depolarized membrane potential Endothelial cells have defective oxidative phosphorylation and glycolysis on loss of heme Mitochondrial damage is caused by loss of functional heme-containing Complex IV and partially restored by exogenous heme